関連する実験動画
Updated: Jun 21, 2026

08:44
Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
Published on: November 11, 2014
8.3K
アルファリポ酸サプリメントは,フリードリヒ症の細胞モデルにおける病理学的変化を改善する
Marta Talaverón-Rey1, Diana Reche-López1, Suleva Povea-Cabello1,2
1Centro Andaluz de Biología del Desarrollo (CSIC-Junta de Andalucía-UPO), Universidad Pablo de Olavide, 41013, Seville, Spain.
Orphanet journal of rare diseases
|August 23, 2025
まとめ
アルファリポ酸 (ALA) は,細胞の欠陥を部分的に修正することによって,フリードリヒ症 (FRDA) の治療に希望を示しています. この抗酸化物質はFRDAモデルにおいてフラタキシン発現を増加させ,疾患の表型を逆転させる可能性がある.
科学分野:
- 神経科学
- 遺伝学
- ミトコンドリア生物学
背景:
- フリードライヒ・アタクシア (FRDA) は,自己相性後退性神経変性疾患である.
- FRDAはフラタキシン (FXN) 遺伝子の発現が低下したことで引き起こされます.
- 病理生理学には,ミトコンドリア機能障害,酸化ストレス,エネルギー生産障害が含まれます.
研究 の 目的:
- アルファリポ酸 (ALA) がFRDAに関連した病理学的変化を逆転させるかを評価する.
- FRDA患者の繊維芽細胞と誘発ニューロンに ALAの影響を調査する.
主な方法:
- 鉄の蓄積,脂質過酸化,フラタキシンのレベルを評価した.
- ミトコンドリアのタンパク質発現とバイオエナジェティクスを調べた.
- 患者に由来する線維芽細胞と誘導神経細胞を用いた
主要な成果:
- ALA治療はFRDA線維芽細胞とニューロンの病理的変化を部分的に修正した.
- 最適なALA濃度は,FXN遺伝子のGAAトリプル繰り返し数と相関しています.
- ALAの作用は,ペロキシソーム増殖器活性化ガマ受容体 (PPARγ) の活性化によって媒介される可能性があります.
結論:
- ALA治療は,FRDAの細胞モデルにおけるフラタキシン発現を高めることができる.
- ALAは,FRDAにおける変異フェノタイプを逆転させる可能性を示しています.
- ALAはフリードリヒ症の潜在的治療薬である.
関連する概念動画
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

